Danske Bank A S Has $159,000 Stock Holdings in Henry Schein, Inc. $HSIC

Key Points

• Danske Bank A/S reduced its stake in Henry Schein by 88.1% in Q4, selling 15,485 shares and retaining 2,100 shares worth $159,000.
• Henry Schein beat Q1 estimates with $1.32 EPS (vs. $1.20 est.) and $3.37B revenue, and reaffirmed FY‑2026 EPS guidance of 5.230–5.370, but the stock traded lower amid mixed analyst reactions.
• Company insiders sold 105,911 shares (~$8.57M) in the last 90 days, while institutional investors own about 96.62% of the stock.

Danske Bank A S reduced its holdings in shares of Henry Schein, Inc. (NASDAQ:HSIC - Free Report) by 88.1% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 2,100 shares of the company's stock after selling 15,485 shares during the period. Danske Bank A S's holdings in Henry Schein were worth $159,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in HSIC. CYBER HORNET ETFs LLC acquired a new stake in Henry Schein during the second quarter valued at approximately $25,000. MUFG Securities EMEA plc acquired a new position in shares of Henry Schein in the 2nd quarter worth approximately $27,000. Flagship Harbor Advisors LLC bought a new position in shares of Henry Schein during the 4th quarter worth approximately $30,000. Steph & Co. bought a new position in shares of Henry Schein during the 4th quarter worth approximately $52,000. Finally, Tema Etfs LLC acquired a new stake in Henry Schein in the 4th quarter valued at $56,000. Institutional investors own 96.62% of the company's stock.

Henry Schein Trading Down 2.6%

HSIC stock opened at $72.44 on Thursday. The company has a quick ratio of 0.76, a current ratio of 1.36 and a debt-to-equity ratio of 0.59. Henry Schein, Inc. has a twelve month low of $61.94 and a twelve month high of $89.29. The company has a market cap of $8.31 billion, a P/E ratio of 21.89, a PEG ratio of 2.20 and a beta of 0.82. The business has a fifty day moving average of $76.32 and a 200-day moving average of $75.00.

Henry Schein (NASDAQ:HSIC - Get Free Report) last posted its quarterly earnings results on Tuesday, May 5th. The company reported $1.32 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.20 by $0.12. The business had revenue of $3.37 billion for the quarter, compared to analysts' expectations of $3.34 billion. Henry Schein had a return on equity of 15.44% and a net margin of 2.95%.The firm's quarterly revenue was up 6.3% compared to the same quarter last year. During the same quarter last year, the business earned $1.15 earnings per share. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. As a group, equities research analysts expect that Henry Schein, Inc. will post 5.3 EPS for the current year.

Insider Buying and Selling

In other Henry Schein news, EVP Mark E. Mlotek sold 5,925 shares of the firm's stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $80.80, for a total value of $478,740.00. Following the transaction, the executive vice president directly owned 80,554 shares of the company's stock, valued at approximately $6,508,763.20. This trade represents a 6.85% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Kurt P. Kuehn sold 2,844 shares of Henry Schein stock in a transaction on Tuesday, March 10th. The stock was sold at an average price of $78.96, for a total transaction of $224,562.24. Following the sale, the director directly owned 15,420 shares of the company's stock, valued at $1,217,563.20. This represents a 15.57% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 105,911 shares of company stock worth $8,574,982. 0.89% of the stock is currently owned by company insiders.

Key Headlines Impacting Henry Schein

Here are the key news stories impacting Henry Schein this week:

• Positive Sentiment: Q1 results beat expectations: HSIC reported $1.32 EPS on $3.37B revenue, topping consensus and showing 6.3% revenue growth and margin improvement — a core reason investors bought the stock after the print. Henry Schein Reports First Quarter 2026 Financial Results
• Positive Sentiment: Dental strength and margin expansion were highlighted by management and reporters, supporting the beat and the company’s message of market‑share gains. Reuters: Henry Schein reaffirms annual profit forecast, beats Q1 estimates
• Positive Sentiment: Analyst commentary and screens emphasize HSIC’s value characteristics (attractive P/E, stable cash flows), with Zacks flagging the stock as a strong value pick for some investors. Here's Why Henry Schein (HSIC) is a Strong Value Stock
• Neutral Sentiment: Company reaffirmed FY‑2026 EPS guidance (5.230–5.370) and revenue range roughly in line with consensus — guidance was maintained, not raised, so this is reassuring but not a catalyst. Press release / guidance
• Neutral Sentiment: Earnings call transcript and slide deck are available for deeper detail on segment trends and margin drivers — useful for investors doing diligence. Q1 2026 Earnings Call Transcript
• Neutral Sentiment: Several roundup pieces note mixed analyst views on HSIC — debate centers on execution of margin improvement and growth sustainability rather than any single, clear directional factor. Analysts’ Opinions Are Mixed on These Healthcare Stocks
• Negative Sentiment: At least one shop cut its price target (Mizuho lowered PT from $88 to $82 and set a neutral rating), which can pressure the stock via reduced analyst upside and sentiment. Tickerreport: Mizuho price target cut
• Negative Sentiment: Despite the beat, the stock is trading lower with above‑average volume (investors appear to be selling into the print, possibly locking in gains or reacting to the mixed analyst tone). MarketWatch: stock underperforms peers

Analysts Set New Price Targets

A number of analysts have weighed in on the company. BTIG Research initiated coverage on Henry Schein in a research note on Thursday, April 16th. They set a "neutral" rating for the company. Citigroup assumed coverage on shares of Henry Schein in a research note on Wednesday, April 15th. They issued a "buy" rating and a $100.00 target price on the stock. Morgan Stanley reaffirmed an "underweight" rating and issued a $64.00 target price (up from $61.00) on shares of Henry Schein in a report on Friday, April 24th. Leerink Partners reissued a "market perform" rating on shares of Henry Schein in a report on Monday, March 9th. Finally, Robert W. Baird set a $97.00 price target on shares of Henry Schein in a research report on Wednesday. Six research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and an average target price of $86.83.

Henry Schein Company Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.

Want to see what other hedge funds are holding HSIC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Henry Schein, Inc. (NASDAQ:HSIC - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.